Drugs / D150
last change Nov 2025 re-read 9 days ago

D150

Investigated by
Chong Kun Dang Pharmaceutical

Trials 16

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 116 trials
Phase 1 NCT07304726 Oct → Nov 2025 type 2 diabetes mellitus Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT07304700 Oct → Nov 2025 type 2 diabetes mellitus Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT07304687 Oct → Nov 2025 type 2 diabetes mellitus Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT05897216 Jul 2023 type 2 diabetes mellitus Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT05928637 Jul → Aug 2023 type 2 diabetes mellitus Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT05952219 Jun 2023 type 2 diabetes mellitus Chong Kun Dang Pharmaceutical Unknown No outcome recorded
Phase 1 NCT05816759 May → Jun 2023 type 2 diabetes mellitus Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT05741437 Apr → Aug 2023 type 2 diabetes mellitus Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT05719155 Feb → Mar 2023 type 2 diabetes mellitus Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT05452525 Jul → Aug 2022 type 2 diabetes mellitus Chong Kun Dang Pharmaceutical Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 16 sources stand behind the page.

FieldValueCited text
Known as D150 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05452525 ↗
15

NCT04706286 ↗

NCT05719155 ↗

NCT05816759 ↗

NCT04810676 ↗

NCT05897216 ↗

NCT05741437 ↗

NCT07304687 ↗

NCT04334213 ↗

NCT05347576 ↗

NCT05928637 ↗

Show 5 more sources

Route Oral “single oral administration under fed condition” NCT04260438 ↗